ArticleFrontiers in immunology2024

Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy.

Michael J NewmanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.